2 results
Approved WMORecruiting
The objective is to determine whether etidronate can halt or attenuate disease progression in patients with Fahr*s disease or syndrome.
Approved WMORecruiting
Primary Objectives: * to establish - which is the best treatment, MTX or baricitinib, to ensure rapid symptom relief of recent onset UA, based on clinical and patient reported outcomes from baseline to 3 months. Secondary Objective: * to establish…